文献速递肝肾功能剂量调整特殊人群用药

奥卡西平活性代谢物PBPK模型预测肾功能不全患儿药代动力学并调整剂量

Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages.
PubMed 文献 · Br J Clin Pharmacol · 2025-02-17

本研究建立并验证了奥卡西平活性代谢物的生理药代动力学(PBPK)模型,模拟肾功能不全(RI)患儿的药物处置。模型预测误差倍数小于2,并据此提出2–5岁和6–17岁患儿在中度、重度及终末期RI时的剂量调整方案。

要点

  • PBPK模型预测误差倍数小于2,可用于预测奥卡西平在RI患儿中的药代动力学。
  • 2–5岁RI患儿中度、重度、终末期RI剂量分别调整为正常剂量的50%、40%、25%。
  • 6–17岁RI患儿中度、重度、终末期RI剂量分别调整为正常剂量的50%、30%、20%。

核心结论

  • 所建立的PBPK模型是预测肾功能不全患儿奥卡西平剂量的有价值工具。

研究设计与样本

  • 建立并验证奥卡西平活性代谢物的PBPK模型,模拟有或无肾功能不全人群的处置。

主要发现

  • 单次和多次给药模拟结果的误差倍数均小于2。
  • 基于预测,2–5岁患儿中度、重度、终末期RI剂量分别为正常剂量的50%、40%、25%。
  • 基于预测,6–17岁患儿中度、重度、终末期RI剂量分别为正常剂量的50%、30%、20%。

关键数值与推荐

  • 2–5岁患儿中度RI调整至正常剂量50%,重度RI 40%,终末期RI 25%。
  • 6–17岁患儿中度RI调整至正常剂量50%,重度RI 30%,终末期RI 20%。

临床怎么用

  • 临床可参考上述剂量调整方案,为肾功能不全患儿使用奥卡西平提供个体化给药依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Oxcarbazepine (OXC) has been approved as monotherapy or adjunctive therapy for paediatric partial seizures. There are few reports on the pharmacokinetics (PK) of OXC in paediatric patients with renal impairment (RI), especially dosage studies of RI, which are rarely conducted on paediatric patients. This study aimed to predict the PK of OXC in children with RI and to provide recommendations for dose adjustment in this population. METHODS: Physiologically based pharmacokinetic (PBPK) models of the active metabolites of OXC were developed and verified, and their disposition was simulated in populations with or without RI. RESULTS: A fold error value of less than 2 was observed based on the simulated results from PBPK models for single- and multi-dose administration. Based on the predictions for paediatric patients with moderate, severe, and end-stage RI, the dose should be adjusted to 50, 40 and 25% of the normal dose, respectively, in children aged 2-5 years; and 50, 30 and 20%, respectively, in children aged 6-17 years. CONCLUSIONS: The developed PBPK model is a valuable tool for predicting the OXC dosage in paediatric patients with RI.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ke CJ, Liu ST, Qian YD, et al. Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages. Br J Clin Pharmacol. 2025. PMID: 39961585. doi:10.1002/bcp.70016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。